Website Search
ID 15041

Getting the diagnosis of chronic myeloid leukemia, Bud

Description:
Interviewee: Bud. Bud recounts receiving the diagnosis that he had chronic myeloid leukemia. (DNAi Location: Applications > Genes and medicine > Drug design > Bud's Story > "A death sentence")
Transcript:
It was devastating there I didn't know what to do, you know, that's a death sentence. Was then. It was a death sentence. They gave me two or three years is what he gave me and that was eight years ago. I've been into it five now out of eight. So I beat it by five so far but of course that's, you know what it is, Gleevec™ there has helped me out.
Keywords:
chronic myeloid leukemia,location applications,gleevec,dnai,romine,death sentence,cml,interviewee,leukemia,bud,genes,diagnosis,medicine
Creative Commons License This work by Cold Spring Harbor Laboratory is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.

Related content:

15042. The first day of clinical trials for Gleevec, Bud and Yvonne
Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
15043. Bloodcount returns to normal with Gleevec, Bud and Yvonne
CML causes an increased production of white blood cells. Bud and Yvonne talk about the breakthrough that brought Bud's white blood cell count back to normal.
16105. The magic pills, Bud and Yvonne
Yvonne talks about the magic pills Bud took.
15057. Before and after Gleevec, Brian Druker
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
15712. Bud and Yvonne
Bud and Yvonne are delighted by Bud's recovery thanks to Gleevec
15054. Restoring hope with Gleevec, Brian Druker
Brian Druker talks about how Gleevec has restored patients' hope for the future.
15525. How Gleevec works to alleviate symptoms of myeloid leukemia, 3D animation with basic narration
View the animation to find out how the drug Gleevec™ inhibits the molecular cause of chronic myeloid leukemia.
15056. Approval for Gleevec in record time, Brian Druker
Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
15082. Shutting down cancer with Gleevec, Brian Druker
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
15055. Using DNA science to control CML, Brian Druker
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
Cold Spring Harbor Laboratory
CSHL HomeAbout CSHLResearchEducationPublic EventsNewsstandPartner With UsGiving